The estimated Net Worth of Lisa Lynn Decker is at least $911 millier dollars as of 14 June 2024. Dr Decker owns over 977 units of IGM Biosciences stock worth over $704,740 and over the last 5 years he sold IGMS stock worth over $206,722.
Dr has made over 9 trades of the IGM Biosciences stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 977 units of IGMS stock worth $7,406 on 14 June 2024.
The largest trade he's ever made was selling 4,369 units of IGM Biosciences stock on 13 December 2023 worth over $25,253. On average, Dr trades about 788 units every 34 days since 2020. As of 14 June 2024 he still owns at least 60,029 units of IGM Biosciences stock.
You can see the complete history of Dr Decker stock trades at the bottom of the page.
Dr. Lisa L. Decker Ph.D. is the Chief Bus. Officer at IGM Biosciences.
Dr D is 52, he's been the Chief Bus. Officer of IGM Biosciences since . There are 10 older and 9 younger executives at IGM Biosciences. The oldest executive at IGM Biosciences, Inc. is Michael Loberg, 72, who is the Independent Chairman of the Board.
Lisa's mailing address filed with the SEC is C/O IGM BIOSCIENCES, INC., 325 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW, CA, 94043.
Over the last 5 years, insiders at IGM Biosciences have traded over $2,263,330 worth of IGM Biosciences stock and bought 10,358,723 units worth $195,788,133 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Group, Llc Green Jeremy Red... et Bros. Advisors Lp667, L.P.B.... On average, IGM Biosciences executives and independent directors trade stock every 13 days with the average trade being worth of $942,182. The most recent stock trade was executed by Julie Hambleton on 25 July 2024, trading 15,132 units of IGMS stock currently worth $21,033.
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
IGM Biosciences executives and other stock owners filed with the SEC include: